Literature DB >> 33199826

A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer.

Krishna B Singh1, Eun-Ryeong Hahm1, Su-Hyeong Kim1, Stacy G Wendell1, Shivendra V Singh2,3.   

Abstract

A subset of human prostate cancer exhibits increased de novo synthesis of fatty acids, but the molecular driver(s) of this metabolic abnormality remains obscure. This study demonstrates a novel metabolic function of c-Myc (Myc) in regulation of fatty acid synthesis. The role of Myc in regulation of fatty acid synthesis was investigated by: (a) interrogation of the prostate cancer The Cancer Genome Atlas (TCGA) dataset, (b) chromatin immunoprecipitation, and (c) determination of the expression of fatty acid synthesis enzymes and targeted metabolomics using a mouse model and human specimens. The expression of MYC was positively associated with that of key fatty acid synthesis genes including ACLY, ACC1, and FASN in prostate cancer TCGA dataset. Chromatin immunoprecipitation revealed Myc occupancy at the promoters of ACLY, ACC1, and FASN. Prostate-specific overexpression of Myc in Hi-Myc transgenic mice resulted in overexpression of ACLY, ACC1, and FASN proteins in neoplastic lesions and increased circulating levels of total free fatty acids. Targeted metabolomics confirmed increased circulating levels of individual fatty acids in the plasma of Hi-Myc mice and human subjects when compared to corresponding controls. Immunohistochemistry also revealed a positive and statistically significant association in expression of Myc with that of ACC1 in human prostate adenocarcinoma specimens. We propose that Myc-regulated fatty acid synthesis is a valid target for therapy and/or prevention of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33199826      PMCID: PMC7855479          DOI: 10.1038/s41388-020-01553-z

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer.

Authors:  W W He; P J Sciavolino; J Wing; M Augustus; P Hudson; P S Meissner; R T Curtis; B K Shell; D G Bostwick; D J Tindall; E P Gelmann; C Abate-Shen; K C Carter
Journal:  Genomics       Date:  1997-07-01       Impact factor: 5.736

2.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.

Authors:  R B Jenkins; J Qian; M M Lieber; D G Bostwick
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

3.  Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.

Authors:  R Buttyan; I S Sawczuk; M C Benson; J D Siegal; C A Olsson
Journal:  Prostate       Date:  1987       Impact factor: 4.104

4.  Integrative genomic profiling of human prostate cancer.

Authors:  Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald
Journal:  Cancer Cell       Date:  2010-06-24       Impact factor: 31.743

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 6.  Common gene rearrangements in prostate cancer.

Authors:  Mark A Rubin; Christopher A Maher; Arul M Chinnaiyan
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

7.  Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.

Authors:  S I Wang; R Parsons; M Ittmann
Journal:  Clin Cancer Res       Date:  1998-03       Impact factor: 12.531

8.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

Authors:  Katharine Ellwood-Yen; Thomas G Graeber; John Wongvipat; M Luisa Iruela-Arispe; JianFeng Zhang; Robert Matusik; George V Thomas; Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

9.  DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies.

Authors:  Jishan Sun; Wennuan Liu; Tamara S Adams; Jielin Sun; Xingnan Li; Aubrey R Turner; Baoli Chang; Jin Woo Kim; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Prostate       Date:  2007-05-15       Impact factor: 4.104

10.  The mutational landscape of lethal castration-resistant prostate cancer.

Authors:  Catherine S Grasso; Yi-Mi Wu; Dan R Robinson; Xuhong Cao; Saravana M Dhanasekaran; Amjad P Khan; Michael J Quist; Xiaojun Jing; Robert J Lonigro; J Chad Brenner; Irfan A Asangani; Bushra Ateeq; Sang Y Chun; Javed Siddiqui; Lee Sam; Matt Anstett; Rohit Mehra; John R Prensner; Nallasivam Palanisamy; Gregory A Ryslik; Fabio Vandin; Benjamin J Raphael; Lakshmi P Kunju; Daniel R Rhodes; Kenneth J Pienta; Arul M Chinnaiyan; Scott A Tomlins
Journal:  Nature       Date:  2012-07-12       Impact factor: 49.962

View more
  6 in total

1.  Leelamine suppresses cMyc expression in prostate cancer cells in vitro and inhibits prostate carcinogenesis in vivo.

Authors:  Krishna B Singh; Eun-Ryeong Hahm; Shivendra V Singh
Journal:  J Cancer Metastasis Treat       Date:  2021-03-26

2.  ACLY inhibitors induce apoptosis and potentiate cytotoxic effects of sorafenib in thyroid cancer cells.

Authors:  Shou-Sen Huang; Chung-Hsin Tsai; Chi-Yu Kuo; Ying-Syuan Li; Shih-Ping Cheng
Journal:  Endocrine       Date:  2022-06-27       Impact factor: 3.925

3.  Prostate-specific oncogene OTUD6A promotes prostatic tumorigenesis via deubiquitinating and stabilizing c-Myc.

Authors:  Yunhua Peng; Jing Liu; Zhen Wang; Chunping Cui; Tiantian Zhang; Shuangxi Zhang; Peipei Gao; Zhanwu Hou; Huadong Liu; Jianping Guo; Jinfang Zhang; Yurong Wen; Wenyi Wei; Lingqiang Zhang; Jiankang Liu; Jiangang Long
Journal:  Cell Death Differ       Date:  2022-02-25       Impact factor: 12.067

Review 4.  Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?

Authors:  Gio Fidelito; Matthew J Watt; Renea A Taylor
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

Review 5.  The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer.

Authors:  Eleazer P Resurreccion; Ka-Wing Fong
Journal:  Metabolites       Date:  2022-05-27

Review 6.  Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?

Authors:  Laura A Sena; Samuel R Denmeade
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 12.701

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.